Fludarabine, cyclophosphamide and rituximab (FCR) in front line treatment of patients with chronic lymphocytic leukemia (CLL)

被引：0
|
作者：
Grifi, Fatiha [1 ]
Bougherira, Soraya [1 ]
Djenouni, Amel [1 ]
机构：
[1] Univ Hosp Ctr Annaba, Annaba, Algeria
来源：
LEUKEMIA & LYMPHOMA | 2017年 / 58卷
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
99
引用
收藏
页码：94 / 94
页数：1
相关论文
共 50 条
  • [1] Lumiliximab with fludarabine, cyclophosphamide, and rituximab (FCR) for patients with relapsed chronic lymphocytic leukemia (CLL).
    O'Brien, S.
    Byrd, J. C.
    Kipps, T. J.
    Forero-Torres, A.
    Flinn, I. W.
    Wynne, D. I.
    Molina, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 360S - 360S
  • [2] The treatment of complicated and high risk chronic lymphocytic leukemia (CLL) with fludarabine, cyclophosphamide and rituximab (FCR).
    Donthireddy, V
    Shurafa, MS
    Saleh, M
    Kamboj, G
    Wang, D
    Janakiraman, N
    [J]. BLOOD, 2005, 106 (11) : 341B - 341B
  • [3] FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB IN FIRST-LINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): RETROSPECTIVE STUDY
    Ionita, H.
    Ionita, I.
    Cheveresan, M.
    Ionita, M.
    Calamar, D.
    Ionita, C. O.
    Oros, D.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 526 - 526
  • [4] Impact and predictors of reducing prescribed doses of fludarabine, cyclophosphamide and rituximab (FCR) in frontline treatment of chronic lymphocytic leukemia (CLL)
    Kovacs, G.
    Bahlo, J.
    Kluth, S.
    Fink, A. M.
    Cramer, P.
    von Tresckow, J.
    Maurer, C.
    Langerbeins, P.
    Gross-Opphoff-Mueller, C.
    Fischer, K.
    Wendtner, C. -M.
    Kreuzer, K. -A.
    Stilgenbauer, S.
    Hallek, M.
    Eichhorst, B.
    Goede, V.
    [J]. Oncology Research and Treatment, 2015, 38 : 91 - 91
  • [5] Fludarabine, Cyclophosphamide and Rituximab (FCR) As First Line Treatment in Patients with Chronic Lymphocytic Leukemia (CLL): A Long-Term Analysis of the German CLL Study Group (GCLLSG) Registry
    Kutsch, Nadine
    Fink, Anna Maria
    Federhen, Anno
    Giza, Adam
    Robrecht, Sandra
    Stumpf, Janina
    Stoltefuss, Andrea
    Vehling-Kaiser, Ursula
    Koenigsmann, Michael
    Tausch, Eugen
    Schneider, Christof
    Stilgenbauer, Stephan
    Illmer, Thomas
    Schlag, Rudolf
    Doerfel, Steffen
    Gaska, Tobias
    Kiehl, Michael G.
    Fischer, Kirsten
    Eichhorst, Barbara
    Hallek, Michael
    [J]. BLOOD, 2022, 140 : 9879 - 9881
  • [6] Improved survival in patients with relapsed - Refractory chronic lymphocytic leukemia (CLL) treated with fludarabine, cyclophosphamide, and rituximab (FCR) combination.
    Wierda, W
    O'Brien, S
    Faderl, S
    Ferrajoli, A
    Lerner, S
    Wang, XM
    Thomas, D
    Garcia-Manero, G
    Cortes, J
    Kantarjian, H
    Keating, M
    [J]. BLOOD, 2003, 102 (11) : 110A - 110A
  • [7] Combination fludarabine, cyclophosphamide and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL).
    Garcia-Manero, G
    O'Brien, S
    Cortes, J
    Giles, F
    Faderl, S
    Lerner, S
    Albitar, M
    Kantarjian, HM
    Keating, MJ
    [J]. BLOOD, 2000, 96 (11) : 757A - 757A
  • [8] FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB IN FIRST-LINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): RETROSPECTIVE ANALYSIS OF CZECH CLL STUDY GROUP
    Smolej, L.
    Lysak, D.
    Papajik, T.
    Salkova, J.
    Brejcha, M.
    Vozobulova, V.
    Karban, J.
    Hrudkova, M.
    Cmunt, E.
    Turcsanyi, P.
    Jungova, A.
    Krejcova, H.
    Trneny, M.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 373 - 373
  • [9] A high proportion of molecular remission can be obtained with a fludarabine, cyclophosphamide, Rituximab combination (FCR) in chronic lymphocytic leukemia (CLL).
    Keating, M
    Manshouri, T
    O'Brien, S
    Wierda, W
    Kantarjian, H
    Washington, L
    Lerner, S
    Albitar, M
    [J]. BLOOD, 2002, 100 (11) : 205A - 205A
  • [10] Pretreatment Factors Associated with Second Malignancies Occuring After Frontline Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Patients with Chronic Lymphocytic Leukemia (CLL).
    Batty, Nicolas
    Badoux, Xavier C.
    Keating, Michael
    Lin, E.
    Lerner, Susan
    O'Brien, Susan
    Ferrajoli, Alessandra
    Kadia, Tapan
    Burger, Jan A.
    Faderl, Stefan
    Wierda, William G.
    [J]. BLOOD, 2009, 114 (22) : 1339 - 1340
12345